DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20221603

Botulinum toxin: a boon or bane in dentistry

Nagaraju Kamarthi, Sangeeta Malik, Sumit Goel, Swati Gupta, Shubham Sharma

Abstract


Botulinum toxin is a neurotoxin which is produced by the Clostridium botulinum bacteria. It is an anaerobic, gram-positive, spore-forming rod-shaped bacteria which is commonly found in soil, on plants, in water and in the intestinal tracts of animals. All the serotypes of botulinum toxin interfere with neural transmission by blocking the release of acetylcholine. The use of botulinum toxins has revolutionised the treatment of various ophthalmic spastic disorders, Orofacial pain conditions, facial dystonia and periocular wrinkles. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is absolutely necessary to correctly use botulinum toxins in clinical practice. This article is an effort to understand Botulinum toxin and its applications in head and neck.


Keywords


Botulinum toxin, Treatment, Orofacial conditions

Full Text:

PDF

References


Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010; 39:197-207.

Hatheway CL. Clostridium botulinum and other clostridia that produce botulinum neurotoxins. In: Clostridium botulinum–Ecology and Control in Foods. Hauschild AHW, Dodds KL. New York, NY: Marcel Dekker, Inc. 1992;3-10.

Flynn TC. Myobloc. Dermatol Clin. 2004;22:207-11.

Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am AcadDermatol. 2000;43(1):249-59.

Freeman SR, Cohen JL. New Neurotoxins on the Horizon. J Aesth Surg. 2008;28:325-30.

Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin type A in cosmetic facial procedures. Int J Oral Maxillofac Surg. 2011;40:127-33.

Yoshida K. Botulinum Neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins. 2018;10:174.

Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016;38:5.

Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008;26(2):126-35.

Sidebottom AJ, Patel AA, Amin J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg. 2013;51:199-205.

Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, BeneckeR et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. The German Dystonia study Group – GDSG. J Neurol Neurosurg Psych. 1998;64(1):13-17.

Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg. 1997;26(6):458-60.

Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg. 1999;57(8): 916-20.

Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18(6):198-203.

von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61(7):774-8.

Castro WH, Gomez RS, da Silva Oliveira J, Moura MD, Gomez RS. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg. 2005;63(1):20-4.

Wang CC, Wang CP. Preliminary experience with botulinum toxin type A intracutaneous injection for Frey's syndrome. J Chin Med Assoc. 2005;68(10):463-67.

Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-termbenefits of botulinum toxin type A (BOTOX) in chronic dailyheadache: a five-year long experience. J Headache Pain. 2006;7(6):407-12.

Ahn KY, Kim ST. The change of maximum bite force afterbotulinum toxin typea injection for treating masseterichypertrophy. Plast Reconstr Surg. 2007;120(6):1662-6.

Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119(2):711-7.